US OptionsDetailed Quotes
PRME241220P7500
- 0.00
- 0.000.00%
15min DelayClose Dec 20 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover0.00%IV-158.62%PremiumDec 20, 2024Expiry Date4.60Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.61Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Prime Medicine Stock Discussion
Sign in to post a comment
$Prime Medicine (PRME.US)$ Prime Medicine | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-ARCH Venture Fund X, L.P.(11.8%),ARCH Venture Fund X Overage, L.P.(11.8%), etc.
SEC· 17:36
SEC· 17:36
3
5
$Prime Medicine (PRME.US)$
Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson’s Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress
Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson’s Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress
$Prime Medicine (PRME.US)$ Break $5!
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Prime Medicine (PRME.US)$ Live volume approaching 6.8 million
$Prime Medicine (PRME.US)$ Prime Medicine announces collaboration, license agreement with Bristol Myers
Prime Medicine Inc - to Receive $110 Mln Upfront, Potential for $3.5 Bln in Milestones
Prime Medicine Inc - to Receive $110 Mln Upfront, Potential for $3.5 Bln in Milestones
3
No comment yet
J L 7 2 : Master, hello. In your opinion, is this a good thing or a bad thing?
Trytosaveabit OP J L 7 2 : Good!
J L 7 2 Trytosaveabit OP : Thank you for your reply, I still hold a portion
Trytosaveabit OP J L 7 2 : You’re welcome! GL and big profits to ya
J L 7 2 Trytosaveabit OP : 大家一样都赚大钱
